BACKGROUND: Use of current oral calcineurin inhibitors for the treatment of psoriasis is limited by toxicity. OBJECTIVE: Evaluate the safety and efficacy of ISA247, a new oral calcineurin inhibitor, in plaque psoriasis patients. METHODS: This 12-week, randomized, double-blind, placebo-controlled, parallel-group study included 201 plaque psoriasis patients with > or = 10% body surface area involvement. Patients were randomized to placebo, ISA247 0.5 mg/kg/d, and ISA247 1.5 mg/kg/d groups. End points included a 2-point reduction in the Static Global Assessment score and a 75% reduction in the Psoriasis Area and Severity Index. RESULTS: A 2-point SGA reduction was achieved in 0% (placebo), 15.6% (0.5 mg/kg/d), and 45.1% (1.5 mg/kg/d) (P < .0001). A 75% reduction in the Psoriasis Area and Severity Index was achieved in 0% (placebo), 18.2% (0.5 mg/kg/d), and 66.7% (1.5 mg/kg/day) (P < .0001). While serum creatinine increased in patients treated with ISA247 1.5 mg/kg/d, it remained within the normal range. LIMITATIONS: Longer-term studies are needed to evaluate the effect of ISA247 on renal function. CONCLUSION:ISA247 appears safe and effective for treating moderate to severe psoriasis.
RCT Entities:
BACKGROUND: Use of current oral calcineurin inhibitors for the treatment of psoriasis is limited by toxicity. OBJECTIVE: Evaluate the safety and efficacy of ISA247, a new oral calcineurin inhibitor, in plaque psoriasispatients. METHODS: This 12-week, randomized, double-blind, placebo-controlled, parallel-group study included 201 plaque psoriasispatients with > or = 10% body surface area involvement. Patients were randomized to placebo, ISA247 0.5 mg/kg/d, and ISA247 1.5 mg/kg/d groups. End points included a 2-point reduction in the Static Global Assessment score and a 75% reduction in the Psoriasis Area and Severity Index. RESULTS: A 2-point SGA reduction was achieved in 0% (placebo), 15.6% (0.5 mg/kg/d), and 45.1% (1.5 mg/kg/d) (P < .0001). A 75% reduction in the Psoriasis Area and Severity Index was achieved in 0% (placebo), 18.2% (0.5 mg/kg/d), and 66.7% (1.5 mg/kg/day) (P < .0001). While serum creatinine increased in patients treated with ISA247 1.5 mg/kg/d, it remained within the normal range. LIMITATIONS: Longer-term studies are needed to evaluate the effect of ISA247 on renal function. CONCLUSION:ISA247 appears safe and effective for treating moderate to severe psoriasis.
Authors: Antoinette I M van Laarhoven; Ineke M van der Sman-Mauriks; A Rogier T Donders; Mathilde C Pronk; Peter C M van de Kerkhof; Andrea W M Evers Journal: J Invest Dermatol Date: 2014-12-01 Impact factor: 8.551
Authors: Spencer Y Ling; Robert B Huizinga; Patrick R Mayo; Richard Larouche; Derrick G Freitag; Launa J Aspeslet; Robert T Foster Journal: Br J Clin Pharmacol Date: 2014-06 Impact factor: 4.335
Authors: Jehan Alam; Rodrigo G de Souza; Zhiyuan Yu; Michael E Stern; Cintia S de Paiva; Stephen C Pflugfelder Journal: J Ocul Pharmacol Ther Date: 2020-07-23 Impact factor: 2.671
Authors: Matthew A Cunningham; Bobbie Ann Austin; Zhuqing Li; Baoying Liu; Steven Yeh; Chi-Chao Chan; Eddy Anglade; Poonam Velagaleti; Robert B Nussenblatt Journal: Invest Ophthalmol Vis Sci Date: 2008-08-15 Impact factor: 4.799
Authors: Andreas Kuglstatter; Francis Mueller; Eric Kusznir; Bernard Gsell; Martine Stihle; Ralf Thoma; Joerg Benz; Launa Aspeslet; Derrick Freitag; Michael Hennig Journal: Acta Crystallogr D Biol Crystallogr Date: 2011-01-15